How I Practice: Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC
Activity Post-Survey & Application for Credit

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 75% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

* 1. What are your specialty & credentials?

Medical Oncologist (MD/DO)

Surgical Oncologist (MD/DO)

Radiologist (MD/DO)

Hematologist/Oncologist (MD/DO)

Other MD/DO

Trainee/Fellow

Nurse

Pharmacist

Other (please specify)

Question Title

* 2. What is your community of practice?

Academic

Community

Industry

Other (please specify)

Question Title

* 3. Per NCCN guidelines, which of the following is a preferred first-line regimen for cisplatin eligible patients with mUC?

Atezolizumab

Gemcitabine and carboplatin

Nivolumab, gemcitabine, and cisplatin

Pembro + EV

Other (please specify)

Question Title

* 4. Erdafitinib is recommended as a second-line treatment option for patients with which genetic alteration?

ARID1A

FGFR3

KDM6A

TP53

Question Title

* 5. 75yo woman with newly diagnosed PD-L1 positive mUC has a GFR of 25mL/min. According to the EAU guidelines, which of the following would be an appropriate 1L treatment option for her?

Atezo or Pembro

Gemcitabine

Nivolumab

Pembro + EV

Question Title

* 6. A 77-year-old man with mUC and no identifiable genetic alterations receives 1L EV+P and 2L gem + cis. He presents 9 months after completing 2L treatment with progressive disease. Which of the following would be an appropriate 3L treatment for him based on NCCN guidelines?

Atezolizumab

Nivolumab

Pembrolizumab

Sacituzumab govitecan

EVALUATION FORM

Question Title

* 7. Upon completion of this activity, I am able to:

	Strongly agree	Agree	Disagree	Strongly disagree
DESCRIBE efficacy data regarding standard therapies used in the treatment of metastatic urothelial carcinoma	DESCRIBE efficacy data regarding standard therapies used in the treatment of metastatic urothelial carcinoma Strongly agree	DESCRIBE efficacy data regarding standard therapies used in the treatment of metastatic urothelial carcinoma Agree	DESCRIBE efficacy data regarding standard therapies used in the treatment of metastatic urothelial carcinoma Disagree	DESCRIBE efficacy data regarding standard therapies used in the treatment of metastatic urothelial carcinoma Strongly disagree
SELECT appropriate treatment based on the latest guidelines regarding preferred treatment regimens for metastatic urothelial carcinoma	SELECT appropriate treatment based on the latest guidelines regarding preferred treatment regimens for metastatic urothelial carcinoma Strongly agree	SELECT appropriate treatment based on the latest guidelines regarding preferred treatment regimens for metastatic urothelial carcinoma Agree	SELECT appropriate treatment based on the latest guidelines regarding preferred treatment regimens for metastatic urothelial carcinoma Disagree	SELECT appropriate treatment based on the latest guidelines regarding preferred treatment regimens for metastatic urothelial carcinoma Strongly disagree

Question Title

* 8. Please indicate the extent of your agreement with the following statements:

	Strongly agree	Agree	Disagree	Strongly disagree
The faculty for this activity were effective	The faculty for this activity were effective Strongly agree	The faculty for this activity were effective Agree	The faculty for this activity were effective Disagree	The faculty for this activity were effective Strongly disagree

Question Title

* 9. Overall, was this activity fair, balanced and free from commercial bias?

Yes

Question Title

* 10. If no, please explain:

Question Title

* 11. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 12. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Expanded use of novel therapies and appropriate uses in mUC

Application of cutting-edge science in this therapeutic area

Appropriate sequencing of therapeutics

Monitoring and mitigation of TRAEs

Implementation of best practices of my colleagues and leaders

I do not plan on making changes to my practice at this time

Other (explain)

Question Title

* 13. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Lack of knowledge regarding treatment options (patient-related)

Patient adherence/resistance to new therapeutics and/or clinical trial enrollment (patient-related barrier)

Limited knowledge regarding new therapeutics for mUC (provider-level barrier)

Lack of time resources to consider change (practice-related barrier)

Inadequate support staff for pt education/insurance/billing/administrative issues (practice-level barrier)

Insurance reimbursement or legal issues (systems-related barrier)

Lack of access to novel therapeutics due to regulatory approvals/insurance coverage (systems-related barrier)

Other (please specify)

Question Title

* 14. For purposes of certification, please complete the following information. Please note that we will not forward or sell your contact information.

First Name *

Last Name *

Degree/Credentials:

City

State/Province

ZIP/Postal Code *

Country

Email Address (required to receive credit) *

Question Title

* 15. I certify that I have participated in the continuing education activity entitled, "How I Practice : Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC" and claim 0.5 AMA PRA Category 1 Credit^TM.

Yes

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com

How I Practice: Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC*Activity Post-Survey & Application for Credit*

Question Title

* 1. What are your specialty & credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. Per NCCN guidelines, which of the following is a preferred first-line regimen for cisplatin eligible patients with mUC?

Question Title

* 4. Erdafitinib is recommended as a second-line treatment option for patients with which genetic alteration?

Question Title

* 5. 75yo woman with newly diagnosed PD-L1 positive mUC has a GFR of 25mL/min. According to the EAU guidelines, which of the following would be an appropriate 1L treatment option for her?

Question Title

* 6. A 77-year-old man with mUC and no identifiable genetic alterations receives 1L EV+P and 2L gem + cis. He presents 9 months after completing 2L treatment with progressive disease. Which of the following would be an appropriate 3L treatment for him based on NCCN guidelines?

Question Title

* 7. Upon completion of this activity, I am able to:

Question Title

* 8. Please indicate the extent of your agreement with the following statements:

Question Title

* 9. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 10. If no, please explain:

Question Title

* 11. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 12. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 13. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 14. For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*

Question Title

* 15. I certify that I have participated in the continuing education activity entitled, "How I Practice : Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC" and claim 0.5 AMA PRA Category 1 CreditTM.

How I Practice: Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC
Activity Post-Survey & Application for Credit

* 14. For purposes of certification, please complete the following information. Please note that we will not forward or sell your contact information.

* 15. I certify that I have participated in the continuing education activity entitled, "How I Practice : Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC" and claim 0.5 AMA PRA Category 1 Credit^TM.